Robin E. Osterhout
70  results:
Search for persons X
?
 
?
4

Pharmacology and Rationale for Seralutinib in the Treatment..:

Pullamsetti, Soni Savai ; Sitapara, Ravikumar ; Osterhout, Robin...
International Journal of Molecular Sciences.  24 (2023)  16 - p. 12653 , 2023
 
?
7

Editorial: protecting hypoxia‐inducible factor 1a and gut i..:

Danese, Silvio ; Levesque, Barrett G. ; Feagan, Brian G....
Alimentary Pharmacology & Therapeutics.  55 (2022)  6 - p. 735-736 , 2022
 
?
 
?
9

Randomised clinical trial: a phase 1b study of GB004, an or..:

Danese, Silvio ; Levesque, Barrett G. ; Feagan, Brian G....
Alimentary Pharmacology & Therapeutics.  55 (2022)  4 - p. 401-411 , 2022
 
?
10

Cover Image:

Danese, Silvio ; Levesque, Barrett G. ; Feagan, Brian G....
Alimentary Pharmacology & Therapeutics.  55 (2022)  4 - p. , 2022
 
?
11

An orally bioavailable ENPP1-selective inhibitor demonstrat..:

Hu, X. ; Garcia, E. ; Goossens, A....
European Journal of Cancer.  174 (2022)  - p. S125 , 2022
 
?
14

Molecular characterization of type I IFN-induced cytotoxici..:

Jennifer L. Green ; Robin E. Osterhout ; Amy L. Klova...
http://www.sciencedirect.com/science/article/pii/S2372770521001558.  , 2021
 
?
15

The Author(s) Pharmacovigilance and Risk Management Strateg..:

Chazin, Howard D. ; Peters, John R. ; Catterson, Debra M....
Therapeutic Innovation & Regulatory Science.  53 (2019)  2 - p. 249-253 , 2019
 
1-15